<DOC>
	<DOCNO>NCT01416961</DOCNO>
	<brief_summary>This study need assess feasibility integrate therapy current treatment regimen . If study show success formal phase II test study conduct feasibility next step . The first dose level choose study 66Gy radiation tumor LET standard photon therapy . This dose current standard care stage III . If dose find feasible dose LET escalate total dose 74Gy .</brief_summary>
	<brief_title>Integration Neutron Therapy Treatment Plan Stage III Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>IIIA : Histologic cytologic diagnosis ipsilateral mediastinal lymph node involvement , Tumors great 7 cm chest wall invasion , involvement one follow diaphragm , phrenic nerve , mediastinal pleura parietal pericardium hilar mediastinal lymph node involvement . More one mediastinal lymph node enlarge CT scan lymph node positive PET scan Paralyzed leave vocal cord separate lung primary distinct aortopulmonary lymph node CT scan . Evidence tumor extension mediastinum and/or mediastinal structure either time mediastinoscopy , bronchoscopy CT scan . IIIB : Histologic cytologic diagnosis N3 lymph node involvement ; Enlarged N3 lymph node CT scan positive PET scan well . Patient must extension lymph node involvement cervical lymph node supraclavicular lymph node ; Right side primary leave vocal cord paralysis ; Patients nodule lung area involvement . Patients prior surgically resect stage I NSCLC receive adjuvant therapy , stage IIIA B NSCLC eligible . Age ≥ 18 year SWOG performance status 0 1 ( see Appendix ) Adequate organ function evidence Absolute neutrophil count ≥ 1.5 x 10 ( 9 ) /L , Platelet count ≥ 100,000 x 109/L Serum creatinine ≤ 1.5 time institutional upper limit normal ( ULN ) , Calculated creatinine clearance ( CockcroftGault formula ) ≥ 45mL/min , Serum bilirubin ≤ ULN , Transaminases ( SGOT and/or SGPT ) ≤ 1.5 time institutional ULN alkaline phosphatase ≤ 2.5 time ULN , FEV1 ≥ 1 liter DLCO &gt; 50 % predict . Patient undergo brain imaging ( CT scan MRI ) rule brain metastasis . Signed informed consent detail investigational nature study accord institutional federal guideline . Registered Clinical Trials Office Karmanos Cancer Institute/Wayne State University . Prior chemotherapy , radiation malignancy receive thoracic radiotherapy . Patients concurrent malignancy . Patients prior concurrent malignancy allow long treat physician considers unlikely impact clinical outcome patient . Patients peripheral neuropathy ≥ 2 . Serious medical illness include limited uncontrolled congestive heart failure , uncontrolled angina , myocardial infarction cerebrovascular event 6 month registration , history chronic active hepatitis history HIV active bacterial infection eligible . Inability unwillingness take folic acid Vitamin B12 dexamethasone . Pregnant lactating woman . All premenopausal perimenopausal woman urine test pregnancy within week start therapy . All patient child bear potential agree use effective contraceptive method . Patients participate therapeutic investigational study take part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Squamous Cell</keyword>
	<keyword>Non-squamous cell</keyword>
</DOC>